Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Antibody developer KaloBios nets $65.1mm in IPO

Executive Summary

KaloBios Pharmaceuticals Inc. (monoclonal antibodies) has netted $65.1mm through its initial public offering of 8.8mm shares at $8, a steep haircut from the $12-14 range the company was planning on last month (it had also expected to sell just 3.85mm shares). The final IPO terms are closer to what KaloBios had initially set in early January: 8.25mm shares at $8.9.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies